Document:

htgm-ex102_15.htm

EXHIBIT 10.2

 

Amendment No. 1 to Statement of Work No. Two 

 THIS AMENDMENT No. 1 (hereinafter “Amendment 1”) to Statement of Work No. Two is effective as of July 2, 2018 (the “Amendment 1 Effective Date”) by and between HTG Molecular Diagnostics, Inc. (“HTG”) and QIAGEN Manchester Limited (“QIAGEN”).   

Whereas, QIAGEN and HTG entered into that certain Statement of Work No. Two, dated June 2, 2017 (the “Agreement”) and the parties now desire to extend the scope and duration of their Development activities under the Agreement; 

Now, therefore, based upon the above premises, and in consideration of the mutual covenants and conditions contained in the Agreement and herein, the parties agree as follows: 

	
 
	
1.
	
Pursuant to Section 4.2 of the Agreement, QIAGEN and HTG confirm they have exchanged details of their respective additional Development activities for mutual review and approval prior to the full execution of this Amendment 1.  These additional Development activities shall be subject to all terms and conditions of the Agreement. 

	
 
	
2.
	
Pursuant to Section 6.2.1 of the Agreement, QIAGEN and HTG have exchanged their additional estimated Project Costs for mutual review and approval prior to the full execution of this Amendment 1.  These additional Project Costs shall be subject to all terms and conditions of the Agreement. 

	
 
	
3.
	
Except as noted above, the Agreement as originally stated shall remain in full force and effect. 

	
 
	
4.
	
This Amendment may be executed in one or more counterparts, each of which shall be deemed an original, and all of which together shall be deemed to be one and the same instrument.  Facsimile or other electronically transmitted signatures shall be deemed original signatures. 

	
HTG/QIAGEN CONFIDENTIAL
	
Page 1 of 2

 

IN WITNESS WHEREOF, HTG and QIAGEN each has caused this Amendment 1 to be executed by its respective duly authorized representative as of the Amendment 1 Effective Date. 

 

		
	
HTG MOLECULAR DIAGNOSTICS 

By:  /s/ Timothy B. Johnson 

Name: Timothy B. Johnson

Title: President, Chief Executive Officer
	
QIAGEN MANCHESTER LIMITED

By: /s/ Roland Sackers 

Name: Roland Sackers

Title: CFO

 

	
 

 
	
 

 

HTG/QIAGEN CONFIDENTIAL Page 2 of 2htgm-ex103_14.htm

 

	
 
	

	
EXHIBIT 10.3

Amendment No.2 Statement of Work No. Two

THIS AMENDMENT No. 2 (hereinafter "Amendment 2") to Statement of Work No. Two is effective as of August 14, 2018 (the "Amendment 2 Effective Date") by and between HTG Molecular Diagnostics, Inc. ("HTG") and QIAGEN Manchester Limited ("QIAGEN").

Whereas, QIAGEN and HTG entered into that certain Statement of Work No. Two, dated June 2, 2017, and first amended effective July 2, 2018 (the "Agreement") and the parties now desire to extend the scope and duration of their Development activities under the Agreement;

Now, therefore, based upon the above premises, and in consideration of the mutual covenants and conditions contained in the Agreement and herein, the parties agree as follows:

	
 
	
1.
	
Pursuant to Section 4.2 of the Agreement, QIAGEN and HTG confirm they have exchanged details of their respective additional Development activities for mutual review and approval prior to the full execution of this Amendment 2. These additional Development activities shall be subject to all terms and conditions of the Agreement.

	
 
	
2.
	
Pursuant to Section 6.2.1 of the Agreement, QIAGEN and HTG have exchanged their additional estimated Project Costs for mutual review and approval prior to the full execution of this Amendment 2. These additional Project Costs shall be subject to all terms and conditions of the Agreement.

	
 
	
3.
	
Except as noted above, the Agreement as originally stated shall remain in full force and effect.

	
 
	
4.
	
This Amendment may be executed in one more counterparts, each of which shall be deemed an original, and all of which together shall be deemed to be one and the same instrument. Facsimile or other electronically transmitted signatures shall be deemed original signatures.

HTG/QIAGEN CONFIDENTIALPage 1 of 2

 

 

 

IN WITNESS WHEREOF, HTG and QIAGEN each has caused this Amendment 2 to be executed by its respective duly authorized representative as of the Amendment 2 Effective Date.

 

		
	
HTG Molecular Diagnostics, Inc.
	
QIAGEN MANCHESTER LIMITED

	
By: /s/ Timothy B. Johnson
	
By: /s/ Thierry Bernard

	
Name: Timothy B. Johnson
	
Name: Thierry Bernard

	
Title: President and Chief Executive Officer

 
	
Title: Sr. VP, Business Area MDx

 

 

 

 

 

HTG/QIAGEN CONFIDENTIALPage 2 of 2htgm-ex104_16.htm

EXHIBIT 10.4

AMENDMENT No. 2 TO SUPPLEMENT AGREEMENT

This Amendment No. 2 To Supplement Agreement ("Amendment 2") is effective July 2, 2018 ("Amendment 2 Effective Date") and is made by and between QIAGEN Manchester Limited, (“QIAGEN"), HTG Molecular Diagnostics, Inc., ("HTG”) and Bristol-Myers Squibb Company (“BMS").

WHEREAS, BMS, QAGEN and HTG entered Into a Supplement Agreement having an effective date of June 2,

2017 and entered into Amendment No. 1 to Supplement Agreement having an effective date of November 21, 2017 (such agreement, as amended, the "Supplement Agreement"); and

Whereas, BMS, QIAGEN and HTG want to further amend the Supplement Agreement,

NOW THEREFORE, for good and valuable consideration, the receipt and sufficiency of which Is hereby acknowledged, QIAGEN HTG and BMS agree as follows:

1. The sixth paragraph on page one of the Supplement Agreement Is replaced with the following:

WHEREAS, QIAGEN wants to engage HTG to perform certain of the work that Is part of the Project and, HTG is willing to perform the work designated to HTG in the Project Plan (as that term is defined in the Initiation Agreement), as amended by Amendment No. 1 to Project Plan having an effective date of July 2, 2018 and by Amendment No, 2 to Project Plan having an effective date of August 10, 2018, in the form provided to HTG by QIAGEN on October 30, 2017, August 2, 2018 (relating to Amendment No. 1 to Project Plan), and August 9, 2018 (relating to Amendment No. 2 to Project Plan) (the "Work), and BMS is willing to allow QIAGEN to engage HTG to perform the Work;

	
 
	
2.
	
This Amendment 2 shall be governed by and construed in accordance with the laws stipulated in the Supplement Agreement,

	
 
	
3.
	
Except as expressly set forth herein, all the terms and conditions of the Supplement Agreement shall remain unchanged and in full force and effect.

	
 
	
4.
	
This Amendment 2 may be executed in two (2) or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one (1) and the same Instrument. This Amendment 2 may be executed by facsimile or electronic (e.g., .pdf) signatures and such signatures shall be deemed to bind each Party hereto as if they were original signatures.

— Signature page to follow—

Page 1 of 2

 

IN WITNESS WHEREOF, BMS, QIAGEN and HTG have caused this Amendment 2 to be signed by their duly authorized representatives, effective as of the Amendment 2 Effective Date.

 

Bristol-Meyers Squibb Company

By: /s/ George A. Green

Name: George A. Green

Title: Head, Pharmacodiagnostics

Date: August 13, 2018

 

QIAGEN Manchester Limited

By: /s/ Thierry Bernard 

Name: Thierry Bernard 

Title: Sr. VP, Business Area MDx

Date: August 14, 2018

 

HTG Molecular Diagnostics, Inc.

By: /s/ Timothy B. Johnson 

Name: Timothy B. Johnson 

Title: President and Chief Executive Officer 

Date: August 15, 2018

 

 

Page 2 of 2htgm-ex105_12.htm

EXHIBIT 10.5

Amendment No. 3 to Statement of Work No. Two

 THIS AMENDMENT No. 3 (hereinafter "Amendment 3") to Statement of Work No. Two is effective as of September 27, 2018 (the "Amendment 3 Effective Date") by and between HTG Molecular Diagnostics, Inc. ("HTG") and QIAGEN Manchester Limited (“QIAGEN").

Whereas, QIAGEN and HTG entered into that certain Statement of Work No. Two, dated June 2, 2017 ("SOW 2"), first amended effective July 2, 2018 ("Amendment 1"), and again amended effective August 14, 2018 ("Amendment 2") (collectively, the "Agreement") and the parties now desire to modify their profit-sharing arrangement under the Agreement;

Now, therefore, based upon the above premise, and in consideration of the mutual covenants and conditions contained in the Agreement and herein, the parties agree as follows:

1. Solely for purposes of the original development activities contemplated under SOW 2, as exchanged between the parties on October 30, 2017 (the “Original Development Activities"), the profit sharing activities contemplated in paragraph 6.5 of SOW 2 shall commence upon the later of the completion of the Original Development Activities or the Amendment 3 Effective Date, rather than at the end of each calendar quarter. The foregoing modification shall apply only to those Original Development Activities which have been or will be completed and which have not yet been subject to profit-sharing as of the Amendment 3 Effective Date.

2. Solely for purposes of the additional development activities contemplated under Amendment 1 to SOW 2, as exchanged between the parties on August 2, 2018 (the "Amendment 1 Development Activities"), the profit sharing activities contemplated in paragraph 6.5 of SOW 2 shall commence upon the later of the completion of the Amendment 1 Development Activities or the Amendment 3 Effective Date, rather than at the end of each calendar quarter. The foregoing modification shall apply only to those Amendment 1 Development Activities which have been or will be completed and which have not yet been subject to profit-sharing as of the Amendment 3 Effective Date.

3. Except as noted above, the Agreement as originally stated shall remain in full force and effect.

	
 
	
4.
	
This Amendment may be executed in one of more counterparts, each of which shall be deemed an original, and all of which together shall be deemed to be one and the same instrument. Facsimile or other electronically transmitted signatures shall be deemed original signatures.

	
 
	
HTG/QIAGEN CONFIDENTIAL
	
Page 1 of 2

 

IN WITNESS WHEREOF, HTG and QIAGEN each has caused this Amendment 3 to be executed by its respective duly authorized representative as of the Amendment 3 Effective Date.

 

 

HTG MOLECULAR DIAGNOSTICS

 

	
 
	
By: /s/ Timothy B. Johnson
	

 

Name: Timothy B. Johnson

Title: President, Chief Executive Officer

 

 

QIAGEN MANCHESTER LIMITED

 

 

 

By: /s/ Thierry Bernard

 

Name: Thierry Bernard

 

Title:  Sr. VP, Business Area MDx

 

	
 
	
HTG/QIAGEN CONFIDENTIAL
	
Page 2 of 2

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00289-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00289-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00289-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00289-of-00352.parquet"}]]